Individualised treatment
Individualised treatments and the growth of pharmaco-genetics improve the understanding and prediction of the risk of disease, diagnosis and treatment profiled to the genetic make-up of individuals. There is also reduced demand through the prevention of conditions and more complexities into treatment are introduced.
Frequency of mention
Proposed workforce impact
- There could be reduced demand for anaesthetics and ICM.
Sources or references
Additional research questions
- Will complex treatments require complex anaesthetics and ICM management?
- Will there be a market for highly expensive pharmaco-genetic products and what are the incentives for pharmaceutical companies to produce them?
Some of the information in this section is provided by stakeholders and expert groups, and does not necessarily represent the views of the CfWI.
